NOW PUBLISHED!! JPCRR Vol. 12, Issue 4: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social

Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

NOW PUBLISHED!! JPCRR Vol. 12, Issue 3: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @drglenweiss.bsky.social et al. OncoTargets and Therapy ow.ly/KtCZ30pBOTq #PrecisionMedicine

Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer www.lungcancerjournal.info/article/S016... #lcsm #ImmunoOnc #PrecisionMedicine

Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd - Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd - Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher

Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - X: @mtmdphd - Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified

.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO ow.ly/iyIe50Igxhe @myelomacrowd #mmsm

The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 meetings.asco.org/abstracts-pr... #mmsm

Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 - Landau et al. #ASCO25 #Abst 7508 meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505 meetings.asco.org/abstracts-pr... #mmsm #caxtx

Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1 - Quach et al. #ASCO25 Abst 7504 meetings.asco.org/abstracts-pr... #mmsm

Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514 meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx

GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad

Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI) - Park et al. #ASCO25 Abst e17085 meetings.asco.org/abstracts-pr... @TempusAI #pcsm

🔥 Just dropped: 6,000+ reasons to get excited for #ASCO25! From game-changing trials to breakthrough science, the full abstract list is now live @ascocancer.bsky.social 🗓️ Start planning your can’t-miss sessions: meetings.asco.org/abstracts-pr...

Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment - @VStudiale et al. @AoupPisana @TempusAI #ASCO25 Abst 3544 meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine

Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041 meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants - @polanimd et al. #ASCO25 Abst 3572 meetings.asco.org/abstracts-pr... @TempusAI #crcsm #PrecisionMedicine

Cohort builder in Tempus Lens: Querying a large oncology database with generative AI - West et al. @tempusAI #ASCO25 Abstract e13589 meetings.asco.org/abstracts-pr... #hemonc

ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC) - Lee et al. @UCLAHealth @TempusAI #ASCO25 Abst 8060 meetings.asco.org/abstracts-pr... #lcsm #ImmunoOnc #PrecisionMedicine

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #ASCO25

Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology ow.ly/RSt450E2I9U #CCC19 #COVID19nCancer

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) - www.promisestudy.org @PromiseStudy #NCT03689595 #mmsm #wmsm #precisionprevention US adults, age 40-75, qualify for a free screening: 1. African Americans and/or 2. 1st degree relative w/ MM, MGUS, SMM, WM

Germline predisposition in multiple myeloma [Dec 17, 2024] Rodrigues et al. iScience www.sciencedirect.com/science/arti... #mmsm #geneticcounselors 954 unrelated individuals w/ MM & 82 MM families

Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic [Jan 23, 2025] @Erman_Akkus et al. CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #mmsm #geneticcounselors

Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR ow.ly/wC8F50IgpjR #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation [Sep 19, 2024] @KLChohan et al. @BloodJournal ashpublications.org/blood/articl... #lymphoidneoplasia #wmsm

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd

Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction [May 26, 2019] @kaushalpar et al. @AMansfieldMD #ASCO19 Abstract 2621 ascopubs.org/doi/abs/10.1... #PrecisionMedicine #ImmunoOnc #geneticcounselors @MayoCancerCare @TempusLabs

A #mmsm classic -> Vincent Rajkumar (@VincentRK): from Madras to Minnesota for myeloma - @TheLancet ow.ly/ElUQk @eaonc

Robert A. Kyle, MD: Lessons From a Legend [Mar 2019] via @VincentRK @MayoProceedings PDF: ow.ly/PQ6G30nT8OQ #mmsm @RobertK68033234

Program Genealogies: Myeloma at Mayo [Jun 11, 2015] - @VincentRK & @RobertK68033234 from @MayoMyeloma ow.ly/OOi38 #mmsm

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd

Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices - @JLErsek @lorablk @mtmdphd & @EdKimMDLCI #ASCO18 Education Book ow.ly/u4RN30pp97P #NCORP

Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR ow.ly/VZNO30nufXz

Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine Molecular Tumor Board [MTB] [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO ow.ly/7Gln30dvnrx

Quantifying the Value of Molecular Tumor Board: Discordance Rec Rate & Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 et al. @JCOPO_ASCO ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc Table 2

Quantifying the Value of Molecular Tumor Board: Discordance Rec Rate & Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 et al. @JCOPO_ASCO ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc Table 1. Recommendation Discordance Definition